Alzheimer’s Disease (AD) is a devastating disease of brain aging that causes progressive, severe memory loss. There is no effective “drug” to prevent or treat AD and we believe that it is unlikely that any will be developed in the near future. Therefore, other therapeutic interventions are desperately needed.
To meet this need, NeuroEM Therapeutics has developed a first-in-class, self-contained head device (the MemorEM™) to treat AD with electromagnetic waves – a therapy that we have pioneered and tested successfully in AD animal studies with no adverse events seen. Our novel, proprietary technology appears to directly affect the AD process to prevent and reverse memory impairment. The MemorEM head device, which allows for complete mobility during one-hour treatments “in home”, has been successfully used in NeuroEM’s recently-completed Pilot clinical trial that evaluated the safety and efficacy of Transcranial Electromagnetic Treatment (TEMT) in Alzheimer’s patients. In view of its promising effects on memory in this clinical trial, TEMT could be an entirely new bioengineering-based intervention against AD.
Our novel, proprietary technology directly affects the AD process to stop and reverse memory impairment. The MemorEM head device, which allows for complete mobility during one-hour in home treatments, has been successfully used in three recently-completed Pilot clinical trials that evaluated the safety and efficacy of Transcranial Electromagnetic Treatment (TEMT) in Alzheimer’s patients. In view of its promising effects in improving cognitive function and memory in these clinical trials, TEMT is a totally new bioengineering-based technology against AD that appears to actually stop the Alzheimer’s disease process.
In upper box, click for our lead clinical paper.
HIGHLIGHTS FROM OUR THREE CLINICAL STUDIES UTILIZING TEMT IN AD PATIENTS:
Two months of daily in-home TEMT:
- Reversed AD cognitive impairment in multiple measures
- Increased functional connections between neurons in the brain
- Re-balanced the immune system in both brain and blood
18 months of daily in-home TEMT over a 2½ year period:
- Stopped cognitive decline in all cognitive measures over the 2½ year period
- Had no deleterious slide effects
- Effected all AD markers evaluated in blood and Cerebrospinal Fluid (CSF)
- Conclusion: TEMT administration to AD subjects appears to be safe, while providing clinically-significant memory enhancement and evidence of disease modification
TEMT is an investigational device currently under clinical development and not commercially available.